SB 525334
Cat. No.：YN460008
CAS No. ：356559-20-1
| 产品名称: | SB 525334 |
| CAS No.: | 356559-20-1 |
| Chemical Name: | 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]-quinoxaline |
| Synonyms: | SB525334 |
| 分子量: | 343.42 |
| 分子式: | C₂₁H₂₁N₅ |
| SMILES: | CC(C)(C1=NC(C2=CC=CC(C)=N2)=C(C3=CC=C4N=CC=NC4=C3)N1)C |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | SB 525334是一种有效，选择性的转化生长因子β1受体 (ALK5) 抑制剂，IC50为 14.3 nM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Grygielko, E.T., Martin, W.M., Tweed, C., et al.Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritisJ. Pharmacol. Exp. Ther.313(3),943-951(2005)
Higashiyama, H., Yoshimoto, D., Kaise, T., et al.Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosisExp. Mol. Pathol.83,39-46(2007)
Jarman, E.R., Khambata, V.S., Yun Ye, L., et al.A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: Mechanistic pathways driving disease pathophysiologyPhysiol.Rep.2(9),1-19(2014)
Laping, N.J., Everitt, J.I., Frazier, K.S., et al.Tumor-specific efficacy of transforming growth factor-βRI inhibition in Eker ratsClin. Cancer Res.13(10),3087-3099(2007)
Thomas, M., Docx, C., Holmes, A.M., et al.Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotalineAm. J. Pathol.174(2),380-389(2009)
